RUAN Xiang-yan, WANG Yue-jiao. Rational Evaluation of Menopausal Hormone Therapy and the Risk of Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 163-166. DOI: 10.12290/xhyxzz.20200281
Citation: RUAN Xiang-yan, WANG Yue-jiao. Rational Evaluation of Menopausal Hormone Therapy and the Risk of Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 163-166. DOI: 10.12290/xhyxzz.20200281

Rational Evaluation of Menopausal Hormone Therapy and the Risk of Breast Cancer

Funds: 

National Natural Science Foundation of China 81671411

Beijing Natural Science Foundation 7162062

Beijing Municipal Administration of Hospitals' Ascent Plan DFL20181401

More Information
  • Corresponding author:

    RUAN Xiang-yan  Tel: 86-10-52273303, E-mail: ruanxiangyan@ccmu.edu.cn

  • Received Date: November 29, 2020
  • Accepted Date: February 03, 2021
  • Available Online: April 15, 2021
  • Issue Publish Date: May 29, 2021
  • With the increasing awareness of women about menopause, an increasing number of women are taking menopausal hormone therapy(MHT) to relieve relevant symptoms (such as irregular bleeding, hot flashes, sweating, sleep disorder, etc.), genitourinary tract atrophy, and osteoporosis. But the risk of breast cancer has always been one of the major concerns for women using MHT. The main safety issue in MHT is breast cancer. The conflict between MHT and the risk of breast cancer has been a hot topic in the field of gynecological endocrinology. This article aims to tell us how to rationally view the relationship between the two based on evidence-based medicine.
  • [1]
    Parker M, Bucknall M, Jagger C, et al. Population-based estimates of healthy working life expectancy in England at age 50 years: analysis of data from the English Longitudinal Study of Ageing[J]. Lancet Public Health, 2020, 5: e395-e403. DOI: 10.1016/S2468-2667(20)30114-6
    [2]
    North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society[J]. Menopause, 2012, 19: 257-271. DOI: 10.1097/gme.0b013e31824b970a
    [3]
    中国老年学和老年医学学会骨质疏松分会妇产科专家委员会与围绝经期骨质疏松防控培训部. 围绝经期和绝经后妇女骨质疏松防治专家共识[J]. 中国临床医生杂志, 2020, 48: 903-908. https://www.cnki.com.cn/Article/CJFDTOTAL-ZLYS202008011.htm
    [4]
    Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394: 1159-1168. DOI: 10.1016/S0140-6736(19)31709-X
    [5]
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial[J]. JAMA, 2002, 288: 321-333. DOI: 10.1001/jama.288.3.321
    [6]
    McTiernan A, Chlebowski RT, Martin C, et al. Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the Women's Health Initiative randomized trial[J]. J Clin Oncol, 2009, 27: 6135-6143. DOI: 10.1200/JCO.2008.21.7166
    [7]
    Chlebowski RT, Anderson GL, Aragaki AK, et al. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials[J]. JAMA, 2020, 324: 369-380. DOI: 10.1001/jama.2020.9482
    [8]
    Mello ML, Vidal BC, Russo IH, et al. DNA content and chromatin texture of human breast epithelial cells transformed with 17-beta-estradiol and the estrogen antagonist ICI 182, 780 as assessed by image analysis[J]. Mutat Res, 2007, 617: 1-7. DOI: 10.1016/j.mrfmmm.2006.08.013
    [9]
    Ruan X, Mueck AO. The choice of progestogen for HRT in menopausal women: breast cancer risk is a major issue[J]. Horm Mol Biol Clin Investig, 2018, 37: 1-22. http://www.degruyter.com/_language/en?uri=%2Fdocument%2Fdoi%2F10.1515%2Fhmbci-2018-0019%2Fhtml
    [10]
    Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention[J]. Biochim Biophys Acta, 2006, 1766: 63-78. http://europepmc.org/abstract/MED/16675129
    [11]
    Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol[J]. Climacteric, 2019, 22: 483-488. DOI: 10.1080/13697137.2019.1582624
    [12]
    Fournier A, Berrino F, Riboli E, et al. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort[J]. Int J Cancer, 2005, 114: 448-454. DOI: 10.1002/ijc.20710
    [13]
    Ruan X, Neubauer H, Yang Y, et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells[J]. Climacteric, 2012, 15: 467-472. DOI: 10.3109/13697137.2011.648232
    [14]
    Mohammed H, Russell IA, Stark R, et al. Progesterone receptor modulates ERalpha action in breast cancer[J]. Nature, 2015, 523: 313-317. DOI: 10.1038/nature14583
    [15]
    纪树峰, 吴爱国, 杨华峰. 黄体酮受体膜成分-1的表达与乳腺癌的恶性表型有关[J]. 南方医科大学学报, 2012, 32: 635-63. DOI: 10.3969/j.issn.1673-4254.2012.05.010

    Ji SF, Wu AG, Yang HF. Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer[J]. Nan Fang Yi Ke Da Xue Xue Bao, 2012, 32: 635-638. DOI: 10.3969/j.issn.1673-4254.2012.05.010
    [16]
    Zhao Y, Ruan X, Wang H, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: A xenograft model[J]. Maturitas, 2017, 102: 26-33. DOI: 10.1016/j.maturitas.2017.05.007
    [17]
    Ruan X, Gu M, Cai G, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: An in-vitro and xenograft study[J]. Maturitas, 2019, 123: 1-8. DOI: 10.1016/j.maturitas.2019.01.015
    [18]
    Ruan X, Zhang Y, Mueck AO, et al. Increased expression of progesterone receptor membrane component 1 is associated with aggressive phenotype and poor prognosis in ER-positive and negative breast cancer[J]. Menopause, 2017, 24: 203-209. DOI: 10.1097/GME.0000000000000739
    [19]
    中华医学会妇产科学分会绝经学组. 中国绝经管理与绝经激素治疗指南(2018)[J]. 协和医学杂志, 2018, 9: 512-525. DOI: 10.3969/j.issn.1674-9081.2018.06.007

    Menopause Group, Obstertrics and Gynecology Branch, Chinese Medical Association. 2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J]. Xie He Yi Xue Za Zhi, 2018, 9: 512-525. DOI: 10.3969/j.issn.1674-9081.2018.06.007
    [20]
    张雪, 董晓平, 管雅喆, 等. 女性乳腺癌流行病学趋势及危险因素研究进展[J]. 肿瘤防治研究, 2021, 48: 87-92. DOI: 10.3971/j.issn.1000-8578.2021.20.0498

    Zhang X, Dong XP, Guan YZ, et al. Research Progress on Epidemiological Trend and Risk Factors of Female Breast Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48: 87-92. DOI: 10.3971/j.issn.1000-8578.2021.20.0498
    [21]
    Giordano SH. Breast Cancer in Men[J]. N Engl J Med, 2018, 378: 2311-2320. DOI: 10.1056/NEJMra1707939
  • Related Articles

    [1]YAO Ru, YANG Xu, QU Yang, LIAN Jie, ZHANG Jiahui, HUANG Xin, CHEN Chang, REN Xinyu, PAN Bo, ZHOU Yidong, SUN Qiang. PTEN Mutation Related Unilateral Multicentric, Synchronous and Metachronous Bilateral Breast Cancer: Three Case Reports[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(4): 916-920. DOI: 10.12290/xhyxzz.2023-0550
    [2]CHEN Rong. Interpretation on the 2023 Chinese Menopause Symptom Management and Menopausal Hormone Therapy Guidelines[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(3): 514-519. DOI: 10.12290/xhyxzz.2023-0190
    [3]CHEN Xiao-han, YU Qi. Protective Effect of Estrogen on Infection of Respiratory Virus[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 179-183. DOI: 10.12290/xhyxzz.20200202
    [4]ZHOU Wen-jie, WU Jie. Menopausal Hormone Therapy and Female Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 157-162. DOI: 10.12290/xhyxzz.20200285
    [5]XIE Mei-qing, XIE Xiao-qian. Benefits and Risks of Menopausal Hormone Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(2): 151-156. DOI: 10.12290/xhyxzz.2021-0130
    [6]Ying XU, Ya-li XU, Zhe WANG, Yan LIN, Chang-jun WANG, Qiang SUN. Menopausal Hormone Therapy Increases the Risk of Breast Cancer:Interpretation on an Article Published in the Lancet Sep. 2019[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(5): 621-625. DOI: 10.3969/j.issn.1674-9081.2020.05.020
    [7]Yan-na ZHANG, Yi-dong ZHOU, Feng MAO, Ru YAO, Qiang SUN. Prognostic Value of Progesterone Receptor and Ki-67 Combination in Hormone Receptor Positive Grade 2 Early-stage Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 539-545. DOI: 10.3969/j.issn.1674-9081.2019.05.019
    [8]Qi YU. 2018 Chinese Guideline on Menopause Management and Menopause Hormone Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(6): 512-525. DOI: 10.3969/j.issn.1674-9081.2018.06.007
    [9]Ying XU, Yan LIN, Chang-jun WANG, Qiang SUN. Consensus and Controversy: Menopausal Hormone Therapy and the Risk of Breast Carcinoma[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(4): 332-335. DOI: 10.3969/j.issn.1674-9081.2018.04.008
    [10]Ming-sheng MA, Xü-de ZHANG, Min WEI, Shi-min ZHAO, Zheng-qing QIU. Efficacy of Low Dose Corticosteroid Therapy in Duchenne Muscular Dystrophy[J]. Medical Journal of Peking Union Medical College Hospital, 2014, 5(4): 384-388. DOI: 10.3969/j.issn.1674-9081.2014.04.006

Catalog

    Article Metrics

    Article views (380) PDF downloads (48) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close